Endo’s Par Delivers On Nevakar Alliance With First Launch
Launch Of Pre-Mixed Ephedrine Sulfate Follows 2018 Deal With 505(b)(2) Specialist
Endo’s Par has announced the first launch under a longstanding US collaboration with 505(b)(2) specialist Nevakar, in the form of pre-mixed ephedrine sulfate injection in a ready-to-use 50mg/10ml single-use vial.
You may also be interested in...
Endo maintains that it will continue to drive revenue and EBITDA growth via business development opportunities, after the advent of generic competition to its lucrative Vasostrict injectable led the firm to disclose potentially catastrophic Q2 profitability guidance.
Endo still sees significant potential in Vasostrict despite the onset of competition. Meanwhile, the firm says it is focusing on “optimizing” its generics business.
Hundreds more jobs are to go at Endo under further cost-cutting measures, including the closure of multiple sites serving the US-based player’s Generics business. Management discussed the issue on Endo’s third-quarter earnings call.